Advertisement

Journal of Neurology

, Volume 258, Issue 7, pp 1234–1239 | Cite as

Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2

  • Donald S. McCorquodaleIII
  • Gladys Montenegro
  • Ainsley Peguero
  • Nicole Carlson
  • Fiorella Speziani
  • Justin Price
  • Sean W. Taylor
  • Michel Melanson
  • Jeffery M. Vance
  • Stephan ZüchnerEmail author
Original Communication

Abstract

Charcot-Marie-Tooth (CMT) disease is among the most common inherited neurological disorders. Mutations in the gene mitofusin 2 (MFN2) cause the axonal subtype CMT2A, which has also been shown to be associated with optic atrophy, clinical signs of first motor neuron involvement, and early onset stroke. Mutations in MFN2 account for up to 20–30% of all axonal CMT type 2 cases. To further investigate the prevalence of MFN2 mutations and to add to the genotypic spectrum, we sequenced all exons of MFN2 in a cohort of 39 CMT2 patients. We identified seven variants, four of which are novel. One previously described change was co-inherited with a PMP22 duplication, which itself causes the demyelinating form CMT1A. Another mutation was a novel in frame deletion, which is a rare occurrence in the genotypic spectrum of MFN2 characterized mainly by missense mutations. Our results confirm a MFN2 mutation rate of ~15–20% in CMT2.

Keywords

Charcot-Marie-Tooth disease CMT2 CMT2A Mitofusin 2 MFN2 Inherited peripheral neuropathies 

Notes

Acknowledgments

The participation of the patients and families in this study is gratefully acknowledged. The study was supported by grants by the Charcot-Marie-Tooth Association (to S.Z.) and the National Institute of Neurological Disorders and Stroke (to S.Z., R01NS052767).

Conflict of interest

Drs. Vance and Züchner are part of a license agreement with Athena Diagnostics Inc.

References

  1. 1.
    Braathen GJ, Sand JC, Lobato A, Hoyer H and Russell MB (2010) Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol 18(1):39–48Google Scholar
  2. 2.
    Braathen GJ, Sand JC, Lobato A, Hoyer H, Russell MB (2010) MFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families. BMC Med Genet 11:48PubMedCrossRefGoogle Scholar
  3. 3.
    Calvo J, Funalot B, Ouvrier RA, Lazaro L, Toutain A, De Mas P, Bouche P, Gilbert-Dussardier B, Arne-Bes MC, Carriere JP, Journel H, Minot-Myhie MC, Guillou C, Ghorab K, Magy L, Sturtz F, Vallat JM, Magdelaine C (2009) Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. Arch Neurol 66:1511–1516PubMedCrossRefGoogle Scholar
  4. 4.
    Casasnovas C, Banchs I, Cassereau J, Gueguen N, Chevrollier A, Martinez-Matos JA, Bonneau D, Volpini V (2010) Phenotypic spectrum of MFN2 mutations in the Spanish population. J Med Genet 47:249–256PubMedCrossRefGoogle Scholar
  5. 5.
    Chung KW, Cho SY, Hwang SJ, Kim KH, Yoo JH, Kwon O, Kim SM, Sunwoo IN, Zuchner S, Choi BO (2008) Early-onset stroke associated with a mutation in mitofusin 2. Neurology 70:2010–2011PubMedCrossRefGoogle Scholar
  6. 6.
    Chung KW, Kim SB, Park KD, Choi KG, Lee JH, Eun HW, Suh JS, Hwang JH, Kim WK, Seo BC, Kim SH, Son IH, Kim SM, Sunwoo IN, Choi BO (2006) Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain 129:2103–2118PubMedCrossRefGoogle Scholar
  7. 7.
    Dyck PJ, Lambert EH (1968) Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 18:603–618PubMedGoogle Scholar
  8. 8.
    Engelfried K, Vorgerd M, Hagedorn M, Haas G, Gilles J, Epplen JT, Meins M (2006) Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2). BMC Med Genet 7:53PubMedCrossRefGoogle Scholar
  9. 9.
    Hodapp JA, Carter GT, Lipe HP, Michelson SJ, Kraft GH, Bird TD (2006) Double trouble in hereditary neuropathy: concomitant mutations in the PMP-22 gene and another gene produce novel phenotypes. Arch Neurol 63:112–117PubMedCrossRefGoogle Scholar
  10. 10.
    Kijima K, Numakura C, Izumino H, Umetsu K, Nezu A, Shiiki T, Ogawa M, Ishizaki Y, Kitamura T, Shozawa Y, Hayasaka K (2005) Mitochondrial GTPase mitofusin 2 mutation in Charcot-Marie-Tooth neuropathy type 2A. Hum Genet 116:23–27PubMedCrossRefGoogle Scholar
  11. 11.
    Lawson VH, Graham BV, Flanigan KM (2005) Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 65:197–204PubMedCrossRefGoogle Scholar
  12. 12.
    Neusch C, Senderek J, Eggermann T, Elolff E, Bahr M, Schneider-Gold C (2007) Mitofusin 2 gene mutation (R94Q) causing severe early-onset axonal polyneuropathy (CMT2A). Eur J Neurol 14:575–577PubMedCrossRefGoogle Scholar
  13. 13.
    Skre H (1974) Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin Genet 6:98–118PubMedCrossRefGoogle Scholar
  14. 14.
    Verhoeven K, Claeys KG, Zuchner S, Schroder JM, Weis J, Ceuterick C, Jordanova A, Nelis E, De Vriendt E, Van Hul M, Seeman P, Mazanec R, Saifi GM, Szigeti K, Mancias P, Butler IJ, Kochanski A, Ryniewicz B, De Bleecker J, Van den Bergh P, Verellen C, Van Coster R, Goemans N, Auer-Grumbach M, Robberecht W, Milic Rasic V, Nevo Y, Tournev I, Guergueltcheva V, Roelens F, Vieregge P, Vinci P, Moreno MT, Christen HJ, Shy ME, Lupski JR, Vance JM, De Jonghe P, Timmerman V (2006) MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 129:2093–2102PubMedCrossRefGoogle Scholar
  15. 15.
    Wise CA, Garcia CA, Davis SN, Heju Z, Pentao L, Patel PI, Lupski JR (1993) Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication. Am J Hum Genet 53:853–863PubMedGoogle Scholar
  16. 16.
    Zhu D, Kennerson ML, Walizada G, Zuchner S, Vance JM, Nicholson GA (2005) Charcot-Marie-Tooth with pyramidal signs is genetically heterogeneous: families with and without MFN2 mutations. Neurology 65:496–497PubMedCrossRefGoogle Scholar
  17. 17.
    Zuchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, Hamilton SR, Van Stavern G, Krajewski KM, Stajich J, Tournev I, Verhoeven K, Langerhorst CT, de Visser M, Baas F, Bird T, Timmerman V, Shy M, Vance JM (2006) Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 59:276–281PubMedCrossRefGoogle Scholar
  18. 18.
    Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schroder JM, Vance JM (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36:449–451PubMedCrossRefGoogle Scholar
  19. 19.
    Zuchner S, Vance JM (2006) Molecular genetics of autosomal-dominant axonal Charcot-Marie-Tooth disease. Neuromolecular Med 8:63–74PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Donald S. McCorquodaleIII
    • 1
  • Gladys Montenegro
    • 1
  • Ainsley Peguero
    • 1
  • Nicole Carlson
    • 1
  • Fiorella Speziani
    • 1
  • Justin Price
    • 1
  • Sean W. Taylor
    • 2
  • Michel Melanson
    • 2
  • Jeffery M. Vance
    • 1
  • Stephan Züchner
    • 1
    Email author
  1. 1.Department of Human Genetics, John P. Hussman Institute for Human GenomicsUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Department of NeurologyKingston General HospitalKingstonCanada

Personalised recommendations